A prospective, randomized, open-label, controlled trial to compare the safety, tolerability and efficacy of influenza virus vaccine, trivalent, type A and B, live, cold-adapted (CAIV-T) [influenza virus vaccine live] with influenza virus vaccine, trivalent, inactivated (TIV) in children with a history of recurrent respiratory tract infections aged 6 months to less than 72 months
Latest Information Update: 17 May 2012
At a glance
- Drugs Influenza virus vaccine live (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections; Respiratory tract infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 04 Dec 2006 Status change
- 09 Dec 2005 New trial record.